News

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Key Takeaways Sarepta Therapeutics shares were down roughly 17% late Friday morning.The tumble followed a report that a third ...
Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...